The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Subscribe To Our Newsletter & Stay Updated
